Watch NWBO. Know when insiders buy.
One email the day a filing lands. Free.
NWBO
NORTHWEST BIOTHERAPEUTICS INC
0.16
−0.01 −5.88%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
49
WATCH · shorts 49
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $272.9MP/E —DIV YIELD —FCF YIELD -18.24%REV TTM $2.2M +98.6%NET INCOME −$37.7MNET DEBT $51.4M52W 0.15 – 0.32SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $807K | +516.0% | — | −$11.6M | −$9.2M | — | -0.01 | −$7.2M | $198K | −$7.4M | Aug 14 |
| Q1 2026 · Mar 31 | $494K | +31.7% | — | −$10.9M | −$3.1M | — | 0.00 | −$12.5M | $129K | −$12.6M | May 15 |
| Q4 2025 · Dec 31derived | $672K | +190.9% | — | −$13.5M | $1.4M | — | 0.00 | −$14.8M | $905K | −$15.7M | Apr 15 |
| Q3 2025 · Sep 30 | $200K | −44.0% | — | −$14.3M | −$26.8M | — | -0.02 | −$13.9M | $202K | −$14.1M | Nov 14 |
| Q2 2025 · Jun 30 | $131K | −74.3% | — | −$14.8M | −$15.4M | — | -0.01 | −$6.7M | $304K | −$7M | Aug 14 |
| Q1 2025 · Mar 31 | $375K | +32.0% | — | −$17.3M | −$19.3M | — | -0.01 | −$9.4M | $93K | −$9.5M | May 15 |
| Q4 2024 · Dec 31derived | $231K | −48.1% | — | −$18.5M | −$28.2M | — | -0.02 | −$20.2M | $78K | −$20.3M | Apr 15 |
| Q3 2024 · Sep 30 | $357K | −12.1% | — | −$14.8M | −$19.4M | — | -0.02 | −$8.2M | $176K | −$8.4M | Nov 14 |
| Q2 2024 · Jun 30 | $510K | — | — | −$17.5M | −$17.9M | — | -0.02 | −$16.2M | $521K | −$16.7M | Aug 14 |
| Q1 2024 · Mar 31 | $284K | — | — | −$15.7M | −$18.3M | — | -0.02 | −$12.4M | $239K | −$12.6M | May 15 |
| Q4 2023 · Dec 31derived | $445K | — | — | −$15.1M | −$14M | — | -0.01 | −$17M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $406K | — | — | −$13.8M | −$23.5M | — | -0.02 | −$13.9M | $437K | −$14.4M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.4M | — | −$59.9M | −$60.2M | -4365.9% | -0.04 | −$44.8M | $1.5M | −$46.3M | — | — |
| FY2024 · to Dec 31 | $1.4M | — | −$66.5M | −$83.8M | -6062.1% | -0.07 | −$57M | $1M | −$58M | — | — |
| FY2023 · to Dec 31 | $1.9M | — | −$55.5M | −$62.6M | -3240.1% | -0.06 | −$53.6M | — | — | — | — |
| FY2022 · to Dec 31 | $1.7M | — | −$67.2M | −$105M | -6240.8% | -0.10 | −$52.8M | — | — | — | — |
| FY2021 · to Dec 31 | $1M | — | −$52.7M | $179.1M | 17823.5% | -0.06 | −$38.3M | — | — | — | — |
| FY2020 · to Dec 31 | $1.3M | — | −$86.6M | −$529.8M | -41039.6% | -0.73 | −$32.1M | — | — | — | — |
Every number comes from NORTHWEST BIOTHERAPEUTICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.